Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shenghui Tang

Showing results (21-30 of 118) with videos related to

Pageof 12
Sort By:
Scientific Reports|January 20, 2024
Biomechanical characterization of firefighters running under different rescue tasksXinxin Zhang, Haili Feng, Xindai Liu, et al.
American Journal of Respiratory and Critical Care Medicine|October 16, 2002
A decision tree for tuberculosis contact investigationLynn B Gerald, Shenghui Tang, Frank Bruce, et al.
The Oncologist|October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyErin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung CancerChana Weinstock, Sean Khozin, Daniel Suzman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2014
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancerLaleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, et al.
The Lancet. Oncology|April 30, 2022
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trialsMallorie H Fiero, Jessica K Roydhouse, Vishal Bhatnagar, et al.
Journal of Virology|July 23, 2002
Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1Jianming Tang, Shenghui Tang, Elena Lobashevsky, et al.
The Oncologist|June 14, 2015
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerYang-Min Ning, Michael Brave, V Ellen Maher, et al.
JAMA Oncology|October 16, 2015
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug AdministrationDickran Kazandjian, Sean Khozin, Gideon Blumenthal, et al.
The Journal of Infectious Diseases|September 10, 2003
Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white menM Tevfik Dorak, Jianming Tang, Shenghui Tang, et al.
Pageof 12

Showing results (21-30 of 118) with videos related to

Sort By:
Pageof 12
Scientific Reports|January 20, 2024
Biomechanical characterization of firefighters running under different rescue tasksXinxin Zhang, Haili Feng, Xindai Liu, et al.
American Journal of Respiratory and Critical Care Medicine|October 16, 2002
A decision tree for tuberculosis contact investigationLynn B Gerald, Shenghui Tang, Frank Bruce, et al.
The Oncologist|October 9, 2015
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based ChemotherapyErin Larkins, Barbara Scepura, Gideon M Blumenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung CancerChana Weinstock, Sean Khozin, Daniel Suzman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2014
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancerLaleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, et al.
The Lancet. Oncology|April 30, 2022
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trialsMallorie H Fiero, Jessica K Roydhouse, Vishal Bhatnagar, et al.
Journal of Virology|July 23, 2002
Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1Jianming Tang, Shenghui Tang, Elena Lobashevsky, et al.
The Oncologist|June 14, 2015
U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerYang-Min Ning, Michael Brave, V Ellen Maher, et al.
JAMA Oncology|October 16, 2015
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug AdministrationDickran Kazandjian, Sean Khozin, Gideon Blumenthal, et al.
The Journal of Infectious Diseases|September 10, 2003
Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white menM Tevfik Dorak, Jianming Tang, Shenghui Tang, et al.
Pageof 12